Mr. Sheppard Has Been Responsible for Leading Companies to Profitability in Various Industries, Including Atkinson Technologies with Patents on the First Mobile IV System
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces that Michael D. Sheppard, with over 30 years of executive level experience leading companies in various industries and strong connections in the medical field, has joined its Board of Directors.
“We are honored to have such a well-respected executive as Michael Sheppard join our Board of Directors,” said Dr. John Salstrom, President and CEO of Protectus Medical Devices. “His depth of experience, medical industry connections, and instinctive business acumen will certainly be an asset to Protectus as a growing medical devices company.”
Mr. Sheppard has a wealth of experience with emerging growth companies and successful turnarounds. He is currently Chairman and CEO of NMC, Inc., which he joined to restore the company to profitability and credibility in the marketplace. He was formerly the chief executive officer of Atkinson Technology, a medical device company that developed and patented the first mobile IV system, eliminating the dependence on gravity to deliver fluid to the patient.
Prior to joining Atkinson Technology, Mr. Sheppard was the President of New Life Corporation and National Community Foundation, a charitable financial planning company where over $400 million was raised for charities in 152 countries. Mr. Sheppard has over 30 years’ experience in top-level executive positions with both private and public companies, including 12 years with Firestone and five years with Thomas Nelson Publishers as Vice President of mass marketing.
“I am enthused and honored to serve Protectus Medical Devices as a director,” said Michael Sheppard. “After spending substantial time with the product and Protectus Medical’s management team, I am convinced that the innovative Protectus Medical Safety Syringe has the potential to revolutionize the healthcare industry by reducing needlestick injuries and saving lives in the process. I look forward to serving with the Protectus team as we launch this product into the global, medical markets. This firm is in the unique position to DO WELL BY DOING GOOD.”
Mr. Sheppard was honored by President Clinton for raising over $400 million supporting humanitarian efforts worldwide and has served President Bush on the Republican Presidential Roundtable. He was also invited by Senator Frist to represent Tennessee on the Republican Senatorial Inner Circle. Mr. Sheppard is a nationally known speaker on financial matters, sales, marketing and management, whose expertise has been credited with a number of corporate turnarounds and record profitability. Mr. Sheppard received a Masters in Business Administration from Wright State University, a Bachelor of Science in industrial technology from Miami University (Ohio) and an Associate Degree in electrical engineering from Sinclair College (Ohio).
Announcing international patent protection status on August 27th, the Company's lead product, the Protectus Medical Safety Syringe, is an automatic, self-sheathing hypodermic safety syringe. The Protectus Medical Safety Syringe is designed to significantly reduce or eliminate accidental needlestick injuries that have plagued the healthcare workplace for decades. More information about Protectus Medical Devices may be found at the Company's corporate website at www.protectusmedical.com.
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.
Contacts:
E-18 Corp.
John Salstrom, President and CEO
1-800-778-8438
moreinfo@protectusmedical.com
or
Financial
Communications Contact:
Trilogy Capital Partners
Darren
Minton, Vice President
Toll-free: 800-592-6067
info@trilogy-capital.com
